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line and were thus excluded as not being clearly 
premenopausal. After the inclusion of women who 
had at least 1 year of follow-up and for whom 
menstrual-history data were sufficient at 12 
months, the final study populations included 1885 
women for overall survival and 1837 for disease-
free survival. Among women with amenorrhea, 
there was significant improvement in overall sur-
vival (hazard ratio for death, 0.72; P = 0.04) and 
in disease-free survival (hazard ratio for disease 
recurrence, a second malignant condition, or 
death, 0.65; P<0.001) (Fig. 1A and 1B). 
We also performed a 12-month landmark 
analysis for subgroups of patients on the basis 
of their estrogen-receptor (ER) status. Women 
with ER-positive tumors who had amenorrhea 
had a significantly better outcome than those 
who did not have amenorrhea, with a hazard 
ratio for death of 0.52 (P = 0.002) and a hazard 
ratio for disease recurrence, a second malignant 
condition, or death of 0.51 (P<0.001). By con-
trast, women with ER-negative tumors had a 
similar outcome regardless of whether they had 
amenorrhea, with a hazard ratio for death of 
1.08 (P = 0.76) and a hazard ratio for disease 
recurrence, a second malignant condition, or 
death of 0.96 (P = 0.85).
In the landmark analysis, the percent differ-
ences in drug doses between women with amen-
orrhea and those without amenorrhea were small 
(Fig. 1C). When the differences were evaluated 
according to tumor ER status, study group, and 
specific drug, there was only one instance in 
which the relative difference was more than 3.8%. 
(In this instance, there was a relative increase of 
9.7% in the dose of docetaxel received as part of 
sequential chemotherapy by women with ER-posi-
tive tumors who had amenorrhea.)
Thus, premenopausal women in whom amen-
orrhea developed as a consequence of adjuvant 
therapy had significantly better overall survival 
and disease-free survival than did women with-
out amenorrhea, particularly when the tumor was 
ER-positive. Furthermore, the dose of the che-
motherapy drug that was delivered was not a key 
factor in explaining the differences.
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Paroxysmal	Nocturnal	Hemoglobinuria	— Hemolysis	
before	and	after	Eculizumab
To the Editor: The letter to the Editor by Ber-
zuini et al. (Sept. 2 issue)1 shows in a single ex-
ample that in patients with paroxysmal nocturnal 
hemoglobinuria (PNH) who are receiving eculiz-
umab, intravascular hemolysis is abrogated, but 
extravascular hemolysis becomes apparent, con-
sequent to C3 binding to red cells, specifically to 
the red cells with the PNH phenotype, since they 
lack CD55. Two series involving 41 patients2 and 
31 patients3 had already shown that this interest-
ing phenomenon has been observed regularly in 
patients with PNH who are receiving eculizumab. 
Decreased red-cell survival measured in vivo2 
provided definitive proof of a hemolytic process.
However, from the letter to the Editor by Ber-
zuini and colleagues, readers may get the im-
pression that C3 binding on PNH red cells is au-
tomatically a major clinical problem and that 
prednisone is the answer.  We are concerned about 
such an impression for three reasons. First, in 
most patients, this phenomenon has relatively little 
clinical relevance. For instance, an adequate level 
of hemoglobin may be maintained in a patient 
even when up to 80% of the PNH red cells have 
bound C3 (Fig. 1). Second, patients with PNH 
are facing a long course: in the past, many of 
them have had a variety of serious side effects of 
long-term use of glucocorticoids (such as “moon 
face” appearance, diabetes, hip necrosis, and even 
severe infection), despite the lack of evidence 
that the use of these agents was of any benefit.4 
Third, in the patient reported on by Berzuini et 
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al., the follow-up is far too short to prove that 
prednisone is beneficial. If prednisone is to be 
used to control extravascular hemolysis in pa-
tients with PNH who are receiving eculizumab, 
this should be done in the context of a clinical 
trial. Our experience with 14 patients suggests 
that this approach is not effective. In one patient, 
splenectomy was successful,5 but this operation 
is not free of risk (in terms of thrombosis and 
otherwise), and it cannot be recommended as a 
routine approach.
Fortunately, even the minority of patients who, 
in terms of hemoglobin level, have only a limited 
response to eculizumab usually have improve-
ment in symptoms such as abdominal pain and 
dysphagia, and the risk of thrombosis is proba-
bly decreased considerably among them, regard-
less of their extravascular hemolysis. Eventually, 
C3-mediated extravascular hemolysis might be 
overcome by a new intervention appropriately tar-
geting C3. In the meantime, the last thing one 
would want is to have these patients burdened 
by the side effects associated with the long-term 
use of glucocorticoids (including a higher risk of 
infection), in addition to their infusions of ecu-
lizumab every 2 weeks.
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Figure	1.	Clinical	Course	of	a	50-Year-Old	Patient	with	Severe	Hemolytic	Paroxysmal	Nocturnal	Hemoglobinuria.	
From the time of diagnosis in 2004, the patient required an average of 3 units of packed red cells per month until 
May 2008, when she began to receive eculizumab treatment. After approximately 2 years, apart from normalization 
of the lactate dehydrogenase (LDH) level, there was an increase in glycosylphosphatidylinositol (GPI)−negative red 
cells; concomitantly, the steady-state hemoglobin level was approximately 12 g per deciliter, despite the fact that 
76% of red cells (or 84% of PNH red cells) had bound C3d (see the inset, which shows the results of the flow cyto-
metric analysis of the C3d deposition on a proportion of CD59 cells from the same patient). The reticulocyte count 
remained elevated, indicating continued extravascular hemolysis. The patient did not receive glucocorticoids.  FITC 
denotes fluorescein isothiocyanate, and PE phycoerythrin.
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corrections
Case 27-2010: A 73-Year-Old Woman with Chronic Anemia 
(September 9, 2010;363:1060-8). In the first paragraph of the 
Treatment Goals subsection of Discussion of Management (page 
1065), the fourth sentence should have read “Two — azacitidine 
and decitabine — are hypomethylating agents, which are 
thought to reactivate genes silenced due to hypermethylation in 
myeloid precursors,” rather than “. . . agents, which inactivate 
genes associated with proliferation and survival in myeloid pre-
cursors.” The article has been corrected at NEJM.org.
Performance of Common Genetic Variants in Breast-Cancer 
Risk Models (March 18, 2010;362:986-93). In Table 3 (page 990), 
the chromosome listed for the RS3803662 SNP should have 
been 16q, rather than 10q, and the chromosome listed for 
RS889312 should have been 5q, rather than 16q. The article 
has been corrected at NEJM.org.
Mortality Attributable to Smoking in China (January 8, 2009; 
360:150-9). In the sixth paragraph of the Discussion section, 
beginning “Ezzati and Lopez estimated . . .” (page 156), the 
parenthetical information should have been given in thou-
sands, rather than millions. The article has been corrected at 
NEJM.org.
notices
Notices submitted for publication should contain a mailing 
address and telephone number of a contact person or depart-
ment. We regret that we are unable to publish all notices 
 received. Notices also appear on the Journal’s Web site 
(NEJM.org/medical-conference). The listings can be viewed 
in their entirety or filtered by specialty, location, or month.
Dallas-lEipzig inTErnaTional ValVE 2010
The conference will be held in Dallas, Dec. 9–11.
Contact Dallas-Leipzig International Valve, 7777 Forest Lane, 
Suite C-742, Dallas, TX 75230; or e-mail info@dallas 
leipzigvalve.org; or see http://www.dallasleipzigvalve.org.
inTEnsiVE MEDical spanish & culTural 
coMpETEncy Workshop
The conference will be held in Acapulco, GRO, Mexico, Dec. 
10–17.
Contact Tamara Rios, Rios Associates, 3729 N. Bay Horse 
Loop, Tucson, AZ 85719; or call (520) 907-3318; or see http://
www.medspanish.org.
29Th gEEW
The “Gastroenterology and Endotherapy European Work-
shop” will be held in Brussels, June 20–22.
Contact Nancy Beauprez, Gastroenterology Department, 
Erasme Hospital, Route de Lennik 808, BE-1070 Brussels, 
Belgium; or call (32) 2 555 49 00; or fax (32) 2 555 49 01; or 
e-mail nancy.beauprez@erasme.ulb.ac.be; or see http://www 
.live-endoscopy.com.
